Longevity Health Holdings, Inc.

What they do

Longevity Health Holdings operates as a bio-aesthetics company focused on longevity and healthy aging, selling cosmetic products primarily in the United States through business-to-business, direct-to-consumer, and distributor channels. Its current product lines are Elevai Exosomes and Carmell Secretome, which support skin and hair health. The company has paused further research and development on its regenerative bone and tissue healing pipeline products.

Revenue drivers

• Elevai Exosomes — Cosmetic product line supporting skin and hair health; sold through professional and retail channels; contributes to overall product revenue.
• Carmell Secretome — Cosmetic product line supporting skin and hair health; sold alongside Elevai Exosomes; part of the company's product portfolio.

Recent performance

Annual revenue was $0 in 2023, $50,318 in 2024, and $1.9M in 2025. Latest quarterly revenue declined from $503,612 (June 2025) to $391,764 (March 2026). Net loss improved from $-15.4M in 2023 to $-6.9M in 2025. As of March 31, 2026, cash was $313,396, total assets were $1.6M, total liabilities were $8.5M, and shareholder equity was negative $6.9M.

Strategy

Longevity is focused on commercializing its cosmetic skincare and haircare products in the U.S. through multiple sales channels. The company paused R&D on regenerative bone and tissue healing products. It recently closed a small private placement ($200,000) and appointed a new CEO/Chairman. Management has been pursuing mergers (e.g., with True Health and 20/20 Biolabs) but terminated both agreements. The company is now traded on the OTCQB after being delisted from Nasdaq.

Risks

• Limited commercial experience — The company has limited experience as a commercial entity and may be unable to generate meaningful product revenue.
• Market acceptance — Success depends on gaining significant market acceptance among consumers, physicians, and professional care providers.
• Human tissue product risk — Products derived from human tissue carry potential for disease transmission, which could harm brand and operations.
• Product liability and quality issues — Product liability lawsuits or quality issues could adversely impact the business, financial condition, and results.

Outlook

Management continues to focus on longevity and healthy aging with its cosmetic product lines. It has paused R&D on regenerative healing products. Recent financing is minimal ($200,000 gross), and the company faces significant cash constraints. Potential severance obligations and the need for additional capital are likely ahead.